C4 Therapeutics, Inc.: updates and filings

CCCCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.65

November 16, 2026Market cap $348M

What Ploutos Investor adds for C4 Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 83 daysAround Feb 8, 2027 · for Q4 2026

last Nov 5, 2026next Feb 8, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Results of operations
    Form8-K
  • Sep 25, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 11, 2026Results of operations
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 24, 2026Shareholder vote
    Form8-K
  • Jun 11, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 19, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Officer or director change
    Form8-K
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 29, 2026Annual report to shareholders
    FormARS
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 22, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 10, 2026Amended articles or bylaws
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 11, 2016.

The full analysis

What do C4 Therapeutics's filings show?

The filings are where every one of C4 Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.